Novavax Crecimiento futuro

Future controles de criterios 3/6

Se prevé que los ingresos de Novavax disminuyan a un ritmo anual de 6.2%, mientras que se prevé que sus beneficios anuales crezcan a un ritmo de 82.3% por año. Se espera que el BPA crezca en un 85% al año.

Información clave

71.5%

Tasa de crecimiento de los beneficios

79.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.8%
Tasa de crecimiento de los ingresos	-6.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	12 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 13

Recent updates

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

May 14

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 13

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

May 07

Novavax: Another Day Older And Deeper In

Mar 02

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Mar 02

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Mar 01

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Feb 23

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Sep 06

Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) Outlook

Mar 05

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:NVAX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	613	24	42	-37	3
12/31/2025	586	-116	-693	-236	6
12/31/2024	952	19	289	416	6
3/31/2024	997	-399	-514	-472	N/A
12/31/2023	984	-545	-773	-714	N/A
9/30/2023	1,050	-549	-727	-655	N/A
6/30/2023	1,597	-587	-737	-654	N/A
3/31/2023	1,359	-1,155	-753	-653	N/A
12/31/2022	1,982	-658	-509	-416	N/A
9/30/2022	1,847	-1,322	-728	-641	N/A
6/30/2022	1,291	-1,476	-814	-744	N/A
3/31/2022	1,403	-1,318	-489	-429	N/A
12/31/2021	1,146	-1,744	265	323	N/A
9/30/2021	1,204	-1,075	454	537	N/A
6/30/2021	1,182	-950	593	672	N/A
3/31/2021	919	-615	575	644	N/A
12/31/2020	476	-418	-97	-43	N/A
9/30/2020	205	-273	49	62	N/A
6/30/2020	50	-93	32	37	N/A
3/31/2020	18	-115	-110	-109	N/A
12/31/2019	19	-133	-138	-137	N/A
9/30/2019	16	-150	-160	-158	N/A
6/30/2019	21	-177	-162	-159	N/A
3/31/2019	29	-182	-171	-169	N/A
12/31/2018	34	-185	-186	-185	N/A
9/30/2018	39	-186	-184	-183	N/A
6/30/2018	39	-186	-196	-194	N/A
3/31/2018	35	-186	-169	-166	N/A
12/31/2017	31	-184	N/A	-144	N/A
9/30/2017	26	-190	N/A	-162	N/A
6/30/2017	21	-212	N/A	-181	N/A
3/31/2017	17	-247	N/A	-230	N/A
12/31/2016	15	-280	N/A	-259	N/A
9/30/2016	16	-302	N/A	-249	N/A
6/30/2016	19	-269	N/A	-215	N/A
3/31/2016	31	-210	N/A	-165	N/A
12/31/2015	36	-157	N/A	-126	N/A
9/30/2015	37	-110	N/A	-91	N/A
6/30/2015	39	-96	N/A	-78	N/A
3/31/2015	33	-94	N/A	-77	N/A
12/31/2014	31	-83	N/A	-67	N/A
9/30/2014	33	-65	N/A	-60	N/A
6/30/2014	29	-61	N/A	-59	N/A
3/31/2014	25	-56	N/A	-55	N/A
12/31/2013	21	-52	N/A	-45	N/A
9/30/2013	17	-46	N/A	-36	N/A
6/30/2013	18	-38	N/A	-26	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que NVAX sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.4%).

Beneficios vs. Mercado: Se prevé que NVAX sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que NVAX sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos de NVAX disminuyan en los próximos 3 años (-6.2% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de NVAX disminuyan en los próximos 3 años (-6.2% al año).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de NVAX se prevé que sea elevada dentro de 3 años.

Novavax Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

Consensus EPS estimates upgraded to US$0.55 loss

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.80 loss

Consensus estimates of losses per share improve by 28%

Recent updates

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

New major risk - Financial position

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Novavax, Inc. to Report Q1, 2024 Results on May 10, 2024

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

Novavax, Inc., Annual General Meeting, Jun 13, 2024

Consensus EPS estimates upgraded to US$0.55 loss

New minor risk - Profitability

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.80 loss

President of Research & Development exercised options and sold US$14k worth of stock

Consensus estimates of losses per share improve by 28%

Price target decreased by 20% to US$15.40

Novavax: Another Day Older And Deeper In

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Full year 2023 earnings: EPS and revenues miss analyst expectations

Novavax, Inc. Provides Earnings Guidance for First Quarter and Full Year 2024

Consensus EPS estimates upgraded to US$0.39 loss, revenue downgraded

New minor risk - Share price stability

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024

CEO & Director exercised options and sold US$171k worth of stock

Price target increased by 15% to US$23.25

Novavax, Inc. Announces The Taiwan Food and Drug Administration Grants Emergency Use Authorization for Nuvaxovid™ XBB.1.5 Dispersion for Injection Covid-19 Vaccine (Recombinant, Adjuvanted) (NVX-CoV2601) for Active Immunization to Prevent Covid-19 in Individuals Aged 12 and Older

Novavax, Inc. Announces Changes to Executive Leadership Team

No longer forecast to breakeven

New major risk - Shareholder dilution

Price target increased by 11% to US$24.50

Novavax, Inc. Provides Earnings Guidance for the First Quarter of 2024

Third quarter 2023 earnings released: US$1.26 loss per share (vs US$2.15 loss in 3Q 2022)

No longer forecast to breakeven

Novavax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Novavax's Updates Nuvaxovid COVID-19 Vaccine Receives Positive CHMP Opinion in the EU

Forecast to breakeven in 2024

Consensus estimates of losses per share improve by 11%

Forecast to breakeven in 2024

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ in United Kingdom

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Novavax, Inc. Announces Updated Protein-Based XBB Covid Vaccine Induced Neutralizing Responses Against Emerging Subvariants

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 12%

Novavax, Inc. announced that it expects to receive $84.5 million in funding from SK bioscience Co.,Ltd.

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novavax, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Profitability

Consensus estimates of losses per share improve by 24%

New minor risk - Profitability

New major risk - Share price stability

Novavax's Nuvaxovid™? Receives Full Marketing Authorization in the Eu for the Prevention of Covid

Consensus EPS estimates fall by 35%

Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell Midcap Index

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

No longer forecast to breakeven

Forecast to breakeven in 2025

Novavax, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 16% to US$39.33

Consensus EPS estimates upgraded to US$4.96 loss, revenue downgraded

Consensus revenue estimates decrease by 25%

Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) Outlook

No longer forecast to breakeven

Price target increased by 23% to US$68.33

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Novavax, Inc. announced that it has received $6.75 million in funding from River Private Wealth